Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Mar-Apr;17(2):269-71.
doi: 10.1177/112067210701700220.

Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion

Affiliations
Case Reports

Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion

Z Vatavuk et al. Eur J Ophthalmol. 2007 Mar-Apr.

Abstract

Purpose: To report a case of neovascular glaucoma due to central retinal artery occlusion treated with a single intravitreal injection of bevacizumab.

Methods: A 68-year-old patient with a 10-week history of central retinal artery occlusion presented with neovascularization of the iris and the angle and intraocular pressure of 30 mm Hg. The patient received a single injection of 1.25 mg bevacizumab in 0.1 mL intravitreally.

Results: Iris and angle neovascularization regressed within 48 hours of the injection. Intraocular pressure dropped from 30 to 15 mm Hg, and there was marked improvement in patient comfort. Panretinal photocoagulation was applied 4 weeks after the injection.

Conclusions: Bevacizumab seems to be a useful adjunct to panretinal photocoagulation in the treatment of neovascular glaucoma.

PubMed Disclaimer

Publication types

LinkOut - more resources